Alternative Data for Kezar Life Sciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 50 | Sign up | Sign up | Sign up |
| Webpage traffic | 9,000 | Sign up | Sign up | Sign up |
| Employee Rating | 62 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 1 | Sign up | Sign up | Sign up |
| Facebook Followers | 211 | Sign up | Sign up | Sign up |
| Instagram Followers | 204 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,721 | Sign up | Sign up | Sign up |
| X Followers | 474 | Sign up | Sign up | Sign up |
| X Mentions | 2 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 47 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 41 | Sign up | Sign up | Sign up |
| Linkedin Employees | 43 | Sign up | Sign up | Sign up |
About Kezar Life Sciences
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States.
| Price | $7.13 |
| Target Price | Sign up |
| Volume | 6,248 |
| Market Cap | $51M |
| Year Range | $3.59 - $7.31 |
| Dividend Yield | 0% |
| Analyst Rating | 33% buy |
| Industry | Biotechnology |
In the news
 |
Kezar Life Sciences: FDA grants Type C meeting to discuss zetomipzomibJanuary 9 - Thefly.com |
 |
PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsightFebruary 10 - PR Newswire UK |
|
Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightFebruary 4 - PR Newswire UK |
|
TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsightFebruary 2 - PR Newswire UK |
 |
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trialJanuary 12 - Nature.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 230,000 | -230,000 | -11M | -11M | -1.530 |
| Q2 '25 | 0 | 0 | 0 | -14M | -13M | -1.870 |
| Q1 '25 | 0 | 250,000 | -250,000 | -17M | -16M | -2.000 |
| Q4 '24 | 1M | 260,000 | 520,000 | -20M | -20M | -3.000 |
| Q3 '24 | 0 | 260,000 | -260,000 | -20M | -20M | -2.780 |
Insider Transactions View All
| Schiller Mark C. filed to sell 2,739 shares at $4.3. July 3 '25 |
| Chiang Pichi Luo filed to sell 2,711 shares at $4.3. July 3 '25 |
| Schiller Mark C. filed to sell 33,007 shares at $0.6. July 26 '24 |
| Morningside Venture Investments Ltd filed to sell 5,447,993 shares at $6.9. February 7 '23 |
| Morningside Venture Investments Ltd filed to sell 5,487,993 shares at $7.1. February 7 '23 |
Similar companies
Read more about Kezar Life Sciences (KZR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Kezar Life Sciences
The Market Cap of Kezar Life Sciences is $51M.
Currently, the price of one share of Kezar Life Sciences stock is $7.13.
The KZR stock price chart above provides a comprehensive visual representation of Kezar Life Sciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Kezar Life Sciences shares. Our platform offers an up-to-date KZR stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Kezar Life Sciences (KZR) does not offer dividends to its shareholders. Investors interested in Kezar Life Sciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Kezar Life Sciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
